Results 291 to 300 of about 90,085 (338)
Some of the next articles are maybe not open access.
Annals of the Rheumatic Diseases, 2020
I read with great interest the letter by Spinelli et al published in the Annals of the Rheumatic Diseases .1 The authors describe the existing scientific evidence concerning the potential antiviral activity of chloroquine and hydroxychloroquine (HCQ ...
K. Parperis
semanticscholar +1 more source
I read with great interest the letter by Spinelli et al published in the Annals of the Rheumatic Diseases .1 The authors describe the existing scientific evidence concerning the potential antiviral activity of chloroquine and hydroxychloroquine (HCQ ...
K. Parperis
semanticscholar +1 more source
Update on antimalarials and systemic lupus erythematosus
Current Opinion in Rheumatology, 2020Purpose of review The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of antimalarials in systemic lupus erythematosus (SLE).
G. Ruiz‐Irastorza +2 more
semanticscholar +1 more source
An Overview of Available Antimalarials: Discovery, Mode of Action and Drug Resistance.
Current molecular medicine, 2020Malaria is one of the three most deadly infectious diseases in the world and seriously endangers human health and life. To reduce the public health burden of this disease, scientists have focused on the discovery and development of effective antimalarial
Yu-Qing Tang +3 more
semanticscholar +1 more source
Dermatologic Therapy, 2001
Antimalarial medications have become the parenteral drugs of choice for treating the cutaneous manifestations of lupus erythematosus. The immune-modulating activity of these agents makes them useful in a variety of other dermatoses. With prudent dosage and monitoring, these agents can be used safely and effectively in the treatment and management of ...
M J, Van Beek, W W, Piette
openaire +2 more sources
Antimalarial medications have become the parenteral drugs of choice for treating the cutaneous manifestations of lupus erythematosus. The immune-modulating activity of these agents makes them useful in a variety of other dermatoses. With prudent dosage and monitoring, these agents can be used safely and effectively in the treatment and management of ...
M J, Van Beek, W W, Piette
openaire +2 more sources
The development process for discovery and clinical advancement of modern antimalarials.
Journal of Medicinal Chemistry, 2019Malaria is a devastating disease caused by Plasmodium parasites resulting in approximately 435,000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies.
T. Ashton +7 more
semanticscholar +1 more source
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions
Current Opinion in Rheumatology, 2018Purpose of review The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of glucocorticoids and antimalarials in systemic lupus erythematosus (SLE) and provide recommendations on their current use ...
A. Ugarte +2 more
semanticscholar +1 more source
Current Opinion in Pharmacology, 2018
Over the past decade, new high-throughput phenotypic assays with malaria parasites have been developed, and these were used to screen millions of compounds. This effort, as well as improving older chemical scaffolds and optimising compounds against both known and new drug targets has resulted in the discovery of exciting new pipeline drug candidates ...
Rob Hooft van Huijsduijnen +1 more
openaire +3 more sources
Over the past decade, new high-throughput phenotypic assays with malaria parasites have been developed, and these were used to screen millions of compounds. This effort, as well as improving older chemical scaffolds and optimising compounds against both known and new drug targets has resulted in the discovery of exciting new pipeline drug candidates ...
Rob Hooft van Huijsduijnen +1 more
openaire +3 more sources
Arthritis care & research, 2019
To determine whether offspring from mothers with systemic lupus erythematosus (SLE), exposed in utero to antimalarials, have an increased risk of ocular anomalies during childhood versus unexposed SLE offspring.
R. Gaffar +4 more
semanticscholar +1 more source
To determine whether offspring from mothers with systemic lupus erythematosus (SLE), exposed in utero to antimalarials, have an increased risk of ocular anomalies during childhood versus unexposed SLE offspring.
R. Gaffar +4 more
semanticscholar +1 more source
ChemInform Abstract: Antimalarial t‐Butylperoxyamines.
ChemInform, 2001AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
SUNDAR, N +4 more
openaire +5 more sources
Synthetic peroxides as antimalarials
Medicinal Research Reviews, 2004AbstractThe discovery of artemisinin in 1971 initiated a new era in antimalarial chemotherapy. Although the clinically useful semisynthetic artemisinin derivatives are rapid acting and potent antimalarial drugs, they have short half‐lives and must be administered over a period of 5–7 days, leading to noncompliance and recrudescence.
Yuanqing Tang +2 more
openaire +5 more sources